Refine by
Therapies For Diabetes Articles & Analysis
7 news found
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells. Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. ...
Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance ...
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen ...
The unique multi-modality capabilities of TWO2 therapy have been proven in numerous clinical studies in both Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU). A state-of-the-art Randomized Controlled Trial (RCT) published in 2020 in the clinical journal of the American Diabetes Association (ADA), Diabetes Care, not only ...
("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes. A multi-specific antibody, or multibody, is a human ...
Dr Peter Widdowson becomes CTO & company moves to Norwich Research Park Norwich, UK, July 29 2020 – Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has appointed experienced gene therapy developer Dr Katie Binley as Chief Scientific Officer. ...
ByIkarovec